Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Objectives Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial

aspirin
hemorrhagic stroke
infarct
brain imaging
ischemic stroke
  • 378 views
  • 26 Jan, 2021
  • 175 locations
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH

brain ct
intraventricular hemorrhage
atrial flutter
apixaban
vascular disease
  • 84 views
  • 18 Feb, 2021
  • 93 locations
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation across Danish hospitals and cardiology clinics

dabigatran
vitamin k antagonist
edoxaban
noac
vitamin k
  • 35 views
  • 22 Jan, 2021
  • 25 locations
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

(atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral

arrhythmia
noac
apixaban
vitamin k
vascular disease
  • 42 views
  • 19 Feb, 2021
  • 140 locations
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

conventional dose warfarin (INR 2-3). Low dose of DOAC has the potential to validate this hypothesis. In a first randomized trial comparing full-dose or low-dose apixaban with a placebo during an

warfarin
anticoagulation therapy
aspirin
apixaban 2.5 mg
anticoagulants
  • 7 views
  • 27 Jan, 2021
  • 59 locations
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

with moderate and severe renal insufficiency. We plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC in VTE patients with moderate or severe renal insufficiency in

anticoagulant
vitamin k antagonists
renal function test
rivaroxaban
renal function
  • 5 views
  • 26 Jan, 2021
  • 39 locations
FREEDOM COVID-19 Anticoagulation Strategy

Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era. To date, nearly 13 million people have contracted COVID-19, leading to more than 550,000 deaths worldwide. As the number of affected individuals continues to climb, effective strategies for …

SARS
acute respiratory distress
enoxaparin
coronavirus infection
respiratory distress
  • 20 views
  • 19 Feb, 2021
  • 20 locations
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy, and thus are widely accepted in clinical practice. Meanwhile, after percutaneous coronary intervention (PCI) using the drug-eluting stents due to coronary …

warfarin
embolism
vitamin k antagonist
noac
apixaban
  • 0 views
  • 25 Jan, 2021
  • 1 location
TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation

This study will compare early with late start of treatment with Non-vitamin K oral anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation; it is a registry-based randomized clinical trial (R-RCT) using The Swedish Stroke Register (Riksstroke). Half of the patients will start NOAC early (within 4 …

atrial fibrillation
noac
vitamin k
anticoagulation therapy
fibrillation
  • 52 views
  • 24 Jan, 2021
  • 57 locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

dabigatran
edoxaban
ticagrelor
vitamin k
anticoagulation therapy
  • 112 views
  • 24 Feb, 2021
  • 76 locations